A new study conducted by researchers from the German Rheumatology Research Center Berlin, an institute of the Leibniz Association, and the Charité—Universitätsmedizin Berlin has shed new light on how ...
Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM).